or Try an Advanced Search...

    Technical Analysis for NVCR - NovoCure Limited

    Grade Last Price % Change Price Change
    D 17.35 1.28% 0.22
    NVCR closed up 1.28 percent on Monday, July 1, 2024, on 1.38 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    5 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Down Down
    Historical NVCR trend table...
    Date Alert Name Type % Chg
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Volume Surge Other 1.28%
    Wide Bands Range Expansion 1.28%
    Oversold Stochastic Weakness 1.28%
    180 Bearish Setup Bearish Swing Setup -1.59%
    Wide Bands Range Expansion -1.59%
    Oversold Stochastic Weakness -1.59%
    NR7 Range Contraction -4.46%
    Older End-of-Day Signals for NVCR ...

       Recent Intraday Alerts

    Alert Time
    Possible Inside Day about 6 hours ago
    Up 3% about 6 hours ago
    60 Minute Opening Range Breakout about 7 hours ago
    Up 2% about 7 hours ago
    Down 2 % about 9 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    NVCR Chart by TradingView
    Basic chart:

    Profile

    NovoCure Limited develops and commercializes treatment for solid tumor cancers therapy called the tumor treating fields (TTFields). The company markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. NovoCure Limited also conducts clinical trials for the use of TTFields in brain metastases, advanced non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma. The company markets its products in the United States, as well as in European Union member states, Switzerland, and Japan. NovoCure Limited was founded in 2000 and is based in Saint Helier, Channel Islands.
    Classification
    Sector: Healthcare
    Industry: Medical Instruments & Supplies
    Keywords: Medicine Cancer Clinical Medicine Oncology Tumor Non Small Cell Lung Cancer Ovarian Cancer Pancreatic Cancer Blastoma Small Cell Lung Cancer Glioblastoma Brain Tumor Solid Tumor Cancers Aging Associated Diseases Metastases Brain Cancer Mesothelioma

    Is NVCR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jul 1 Novocure to Report Second Quarter 2024 Financial Results
    Jun 4 A Closer Look at 7 Analyst Recommendations For NovoCure
    Jun 3 NovoCure Tumor Treating Fields decreases progression of brain metastases
    Jun 3 METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
    May 23 TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
    May 14 Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025
    May 3 NovoCure Limited Q1 Earnings: Core Business Accelerating
    May 3 NovoCure Limited (NASDAQ:NVCR) Q1 2024 Earnings Call Transcript
    May 3 NovoCure (NVCR) Q1 2024 Earnings Call Transcript
    May 2 NovoCure Limited (NVCR) Q1 2024 Earnings Call Transcript
    See more NVCR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 42.69
    52 Week Low 10.87
    Average Volume 1,561,212
    200-Day Moving Average 15.39
    50-Day Moving Average 18.65
    20-Day Moving Average 20.23
    10-Day Moving Average 18.41
    Average True Range 1.01
    RSI (14) 34.64
    ADX 29.88
    +DI 14.72
    -DI 28.48
    Chandelier Exit (Long, 3 ATRs) 21.36
    Chandelier Exit (Short, 3 ATRs) 19.76
    Upper Bollinger Bands 24.24
    Lower Bollinger Band 16.22
    Percent B (%b) 0.14
    BandWidth 39.66
    MACD Line -0.68
    MACD Signal Line -0.13
    MACD Histogram -0.5458
    Fundamentals Value
    Market Cap 1.85 Billion
    Num Shares 107 Million
    EPS -1.86
    Price-to-Earnings (P/E) Ratio -9.33
    Price-to-Sales 3.35
    Price-to-Book 4.16
    PEG Ratio -0.47
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 18.72
    Resistance 3 (R3) 18.67 18.18 18.49
    Resistance 2 (R2) 18.18 17.83 18.20 18.41
    Resistance 1 (R1) 17.76 17.61 17.97 17.81 18.34
    Pivot Point 17.27 17.27 17.37 17.29 17.27
    Support 1 (S1) 16.85 16.92 17.06 16.90 16.36
    Support 2 (S2) 16.36 16.70 16.38 16.29
    Support 3 (S3) 15.94 16.36 16.21
    Support 4 (S4) 15.99